Laura Fontana

Summary

Affiliation: Istituto Superiore di Sanit
Country: Italy

Publications

  1. ncbi MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation
    Laura Fontana
    Department of Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161, Rome, Italy
    Nat Cell Biol 9:775-87. 2007
  2. ncbi Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM
    Laura Fontana
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    PLoS ONE 3:e2236. 2008
  3. ncbi Role of microRNAs in haemopoiesis, heart hypertrophy and cancer
    Laura Fontana
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Biochem Soc Trans 36:1206-10. 2008
  4. ncbi Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex
    Marco Gabbianelli
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, 00161 Rome, Italy
    Haematologica 95:1253-60. 2010
  5. ncbi Regulation of monocytopoiesis by microRNAs
    Laura Fontana
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Methods Mol Biol 667:165-76. 2010
  6. ncbi MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation
    Nadia Felli
    Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Proc Natl Acad Sci U S A 102:18081-6. 2005
  7. ncbi Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions
    Maria Vincenza Carriero
    Department of Experimental Oncology, National Cancer Institute, Naples, Italy
    Biol Chem 383:107-13. 2002

Collaborators

Detail Information

Publications7

  1. ncbi MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation
    Laura Fontana
    Department of Haematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161, Rome, Italy
    Nat Cell Biol 9:775-87. 2007
    ....
  2. ncbi Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM
    Laura Fontana
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    PLoS ONE 3:e2236. 2008
    ..Altogether, our studies demonstrate for the first time that antagomir treatment can abolish tumor growth in vivo, specifically in therapy-resistant neuroblastoma...
  3. ncbi Role of microRNAs in haemopoiesis, heart hypertrophy and cancer
    Laura Fontana
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Biochem Soc Trans 36:1206-10. 2008
    ..The present review focuses on the recent literature concerning the role of miRNAs in three different research areas: haematology, cardiology and oncology, with particular focus on the results obtained by our group...
  4. ncbi Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex
    Marco Gabbianelli
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, 00161 Rome, Italy
    Haematologica 95:1253-60. 2010
    ..MicroRNAs (miRs) play a pivotal role in normal hematopoiesis: downmodulation of miR-221/222 stimulates human erythropoietic proliferation through upmodulation of the kit receptor...
  5. ncbi Regulation of monocytopoiesis by microRNAs
    Laura Fontana
    Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Methods Mol Biol 667:165-76. 2010
    ..This occurs through the regulation of key factors involved in hematopoiesis (e.g., transcription factors, growth factor receptors). We, hereby, describe how to investigate the role of miRNAs in monocytopoiesis...
  6. ncbi MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation
    Nadia Felli
    Department of Hematology, Oncology, and Molecular Medicine, Istituto Superiore di Sanita, Rome, Italy
    Proc Natl Acad Sci U S A 102:18081-6. 2005
    ..Furthermore, the results on kit+ erythroleukemic cells suggest a potential role of these miRs in cancer therapy...
  7. ncbi Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions
    Maria Vincenza Carriero
    Department of Experimental Oncology, National Cancer Institute, Naples, Italy
    Biol Chem 383:107-13. 2002
    ....